Display Settings:

Format

Send to:

Choose Destination

    Fundam Clin Pharmacol. 1989;3(5):537-43.

    Model-independent pharmacokinetics of colchicine after oral administration to healthy volunteers.

    Girre C, Thomas G, Scherrmann JM, Crouzette J, Fournier PE.

    Unité de Pharmacologie Clinique, Hôpital Fernand Widal, Paris, France.

    The pharmacokinetics of colchicine were studied after oral administration of three doses (0.5, 1.0 and 1.5 mg) to nine healthy male volunteers according to randomized cross-over design. Plasma and urine samples were collected during 48 h after ingestion, and assayed for colchicine levels by a specific and highly sensitive radio-immunoassay. Pharmacokinetic parameters t1/2 beta, AUC, MRT, CIT/F, CIR, Vd area/F) were calculated by model-independent methods and compared across doses by multiway analysis of variance. Terminal half-life (15.5-19.2 h), mean residence time (15.7-20.3 h), oral systemic (32.2-40.3 l/h) and renal (3.9-4.7 l/h) clearances, and oral volume of distribution (11.4-14.9 l/kg) did not differ significantly between doses, whereas the area under the concentration-time curve was proportional to dose. Our results show that: 1. within the dose range studied (0.5-1.5 mg), the pharmacokinetics of colchicine are linear; 2. monitoring colchicine levels up to 48 hours yields much larger estimates of terminal half-life and volume of distribution than previously reported from considerably shorter studies.

    PMID: 2606428 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Patient drug information

    • Colchicine Oral

      Colchicine relieves swelling and pain caused by attacks of gout or gouty arthritis. It may also be taken regularly to prevent gout or gouty arthritis attacks.